Objectives: To assess the safety and efficacy of a synergistic protocol for treating flaccidity, which is
based on combining different products in order to to treat flaccidity in perimenopausal
and postmenopausal women.
Introduction: Facial ageing is a continuous and multifactorial process caused by different molecular
and cell changes. The decrease in oestrogen levels during menopause plays a key role
as it is linked to a decrease in transforming growth factor beta (TGF-β),1 the main
activator of extracellular matrix proteins (collagen, elastin, HA, reticulin). mesohyal®
redenx contains palmitoyl tripeptide-5, which activates TGF-β2 , helping to restore the
endogenous cutaneous mechanism in perimenopausal and postmenopausal women.
Materials / method: A clinical study was carried out between July and December 2023 involving 13
perimenopausal and postmenopausal patients divided into two groups based on the
degree of ageing. The protocol aimed skin renewal with peels, cell biostimulation with
mesotherapy, volume replacement with filler and homecare treatment to promote and
maintain long-term results. It consisted of 1 session with 20/25 mg/ml cross-linked HA,
3 mesotherapy sessions (15 mg/ml free HA, palmitoyl tripeptide-5, acetyl tetrapeptide-9
and DMAE) and 3 peel sessions (18% lactic acid, 18% glycolic acid, 2% retin@l, 1%
bakuchiol) for m
Results: The clinical results of the two study groups demonstrate noticeable skin rejuvenation,
with reduced pigmentation and improved skin quality. In addition, the replacement of
the facial support structures provides structure and firmness to the skin, thereby
correcting facial sagging. Ex vivo data demonstrated an increase in TGF-β on kin
explants treated with biomimetic peptides and analysed using immunofluorescence
microscopy.
Conclusion: This therapeutic strategy for treating flaccidity is a comprehensive approach that
improves the signs of flaccidity by acting on different skin planes and cellular targets.
Peels are recommended to stimulate skin regeneration, mesotherapy to administer
active ingredients for cellular biostimulation and cross-linked HA fillers to restore facial
volume. Ex vivo studies have shown that peptides act at cellular and tissue levels,
improving fibroblast function and stimulating the synthesis of ECM proteins, resulting in
improved skin quality when tested clinically.
Disclosures
Did you receive any funding to support your research for this TOPIC?
No
Were you provided with any honoraria, payment or other compensation for your work on this study?
No
Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No
Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No
This work was not supported by any direct or non direct funding. It is under the author's own responsability